Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease
Advanced Therapeutic Medicinal Products (ATMP) are a heterogenous group of investigational medicinal products at the forefront of innovative therapies with direct applicability in respiratory diseases. ATMPs include, but are not limited to, stem cells, their secretome, or extracellular vesicles, and...
Main Authors: | Niamh Woods, Ronan MacLoughlin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/10/922 |
Similar Items
-
State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery
by: Hosanna Brave, et al.
Published: (2020-09-01) -
An in vitro visual study of fugitive aerosols released during aerosol therapy to an invasively ventilated simulated patient
by: Marc Mac Giolla Eain, et al.
Published: (2021-01-01) -
Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control
by: Marc Mac Giolla Eain, et al.
Published: (2022-12-01) -
Comparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapy
by: Gavin Bennett, et al.
Published: (2019-04-01) -
In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal Therapy
by: Gavin Bennett, et al.
Published: (2019-02-01)